Form 4 for VCEL Vericel Corp

Accepted 2024-09-05 00:00:00 ET · period of report 2024-09-03 · accession 0001140361-24-040225 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DT	2024-09-05	2024-09-03	VCEL	Hopper Jonathan Mark	Chief Medical Off	M - OptEx	$10.95	+10.0K	68.2K	+17%	+$109.5K
DT	2024-09-05	2024-09-03	VCEL	Hopper Jonathan Mark	Chief Medical Off	S - Sale+OE	$49.83	-10.0K	58.2K	-15%	-$498.3K
DT	2024-09-05	2024-09-03	VCEL	Hopper Jonathan Mark	Chief Medical Off	M - OptEx	$0.00	+10.0K	12.6K	+384%	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2024-09-03	M	A	10,000	$10.95	68,229	D	—	—	(F1) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
2	Common	Common Stock	2024-09-03	S	D	10,000	$49.83	58,229	D	—	—	(F2) The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 28, 2024. (F1) These shares include shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
3	Derivative	Stock Option (Right to Buy)	2024-09-03	M	A	10,000	$0.00	12,604	D	$10.95 · — to 2028-08-20	10,000 Common Stock	(F3) These options, representing the right to purchase 135,000 shares, became exercisable on August 20, 2019, the first anniversary of the date of grant, with 25% vesting and the remaining 75% vesting in equal quarterly installments over three years thereafter, contingent upon continued service to the Company.